Matthew Farren
Associate Director Incyte Corporation
Matt Farren is the KRAS Programs Lead at Incyte, where he has led KRAS-focused discovery efforts since 2021. He brings 10 years of combined experience across the pharmaceutical industry and academia. Prior to joining the Tumor Biology group at Incyte, Matt’s academic research centered on the molecular regulation of dendritic cell differentiation, tumor immunology, and on advancing novel therapeutic strategies for cancers of the gastrointestinal tract.
Seminars
Tuesday 8th September 2026
Panel Discussion: How Do We Build Combination Strategies That Work Across KRAS Alleles, Co Mutations, & Tumor Types?
1:00 pm
- How do KRAS alleles, co‑mutations, and tumor lineage reshape dependency and escape, and what does that mean for choosing the right combination backbone?
- Which combinations have true cross‑context potential, and which are only effective in specific molecular or tumor‑type settings?
- How should we prioritise combinations that balance biological rationale, toxicity constraints, and real‑world feasibility across heterogeneous patient populations?
Tuesday 8th September 2026
Expanding Patient Reach: Developing Novel INCB161734 (KRAS G12D Inhibitors) Combinations That Work Across Heterogeneous Tumors
11:00 am
- Combining KRAS inhibitors with orthogonal agents in novel ways to increase the depth and breadth of efficacy in heterogenous tumors
- Reevaluating ways to broaden, not shrink, the treatable KRAS G12D patient population, avoiding combinations that only benefit narrow biomarker defined subsets
- Mutant-selective KRAS inhibitors enable maximal mutant KRAS inhibition while limiting off-tumor to the extent possible off-tumor activity
